Pharma Pulse: Medicare Price Cuts and Vaccine Wins

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, Nico Saraceno, and let’s get into today’s headlines.

• First up, the $12 billion story. The Centers for Medicare & Medicaid Services—CMS— has unveiled negotiated prices for 15 of the most expensive prescription meds under Medicare, delivering a 44% net savings compared to last year. These discounts go live under the Inflation Reduction Act framework: the second round is effective Jan. 1, 2027; the first round (from 2024) kicks in Jan. 1, 2026. Headline drugs like Ozempic and Wegovy lead the cuts, with roughly 71% off 2024 list prices, bringing monthly cost down significantly. Beyond savings, this sends a signal to manufacturers and payers: value-based pricing and negotiation are becoming a permanent fixture of US drug policy.
• Turning to prevention, a new real-world study shows the impact of childhood pneumococcal conjugate vaccines, or PCVs. In Mexico, incidence of pneumococcal meningitis among children dropped substantially after PCV rollout. Globally, similar declines have been observed, with PCV-10 and PCV-13 reducing pneumococcal meningitis by 48–74% among children under 5. That success underscores the power of immunization, but the emergence of non-vaccine serotypes like 19A remains a challenge, pushing the need for higher-valent vaccines and ongoing surveillance.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.